This is "
very good news
" for Valneva, welcomes its managing director, Franck Grimaud.
A month after the termination of an order for 100 million doses by the British government, the Franco-Austrian biotech publishes "
positive
"
results
of phase 3 trials of its anti-Covid vaccine.
“
The results are very clear,”
says Franck Grimaud.
All the objectives are met.
Our vaccine has a statistically higher level of antibody generation than AstraZeneca.
In terms of effectiveness, it is very close to the best vaccines, with a safety comparable to other inactivated vaccines, that is to say, it is very safe and has very few side effects.
It will be one of the best on the market in terms of tolerance.
"
Read also
Vaccines: why London is torpedoing the French nugget Valneva
This announcement, which was greeted on the stock market by a gain of 32% of the title to nearly 16 euros, is a victory for biotech.
In mid-September, she had to draw a line on a 1.4 billion euro contract with the British government.
London
This article is for subscribers only.
You have 78% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
